Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
about
Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patientsBevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyRole of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells.Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.Is there a role for mitomycin C in metastatic colorectal cancer?Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
P2860
Q31156315-F3B4DBE6-EE4F-4C83-8DB5-EAF79A2B6ED6Q33377361-FDFA8229-036F-4F0F-8CDC-24C5CD5B618EQ33413448-F02BCC0B-139E-40E3-A182-A0FD33A2AB82Q33424387-68794A49-3ACF-4370-BDBE-87832E14AD78Q33507171-1848ABE6-A75A-4A36-9C47-E4E998FF2452Q34333852-02954903-09A7-419A-BE9D-43A78397D42AQ35680674-2C477D4B-0C8D-41F1-801B-4BF08000AA6FQ36083302-1508F464-FB4D-4EDB-B8E5-B1AE28A537AEQ36612624-53A94237-874C-4971-AEAB-6C48366E1FD6Q36615612-2A8A0E6C-3078-46B2-9B7C-852662B96EC9Q37672223-F399B932-7ED8-49C3-9804-EA0BE1C9FD2CQ37740144-F0362297-CB40-4893-8AA2-B0E6102758BCQ39297108-8DC0D2EA-3D66-4A03-811E-D01125E7432FQ43200404-E7F62213-D012-4302-8717-FFCB40C9603BQ43597808-C14D4AC4-486B-46CD-BDCB-E2C5983348BDQ46901745-096A457F-A9A7-4C0F-8A55-58181795C729Q49922743-D7B32B9B-B253-4AC5-8B43-9F6BA8BCB57E
P2860
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@ast
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@en
type
label
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@ast
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@en
prefLabel
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@ast
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@en
P2093
P2860
P356
P1476
Capecitabine and mitomycin C a ...... o fluorouracil and irinotecan.
@en
P2093
A R Norman
J L B Dickson
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602733
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1052159142